Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Natera Inc (NQ: NTRA )

130.39 +3.42 (+2.69%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 7, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Natera Inc

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc... 
Via Benzinga
CEO And President Of Natera Trades $2.4M In Company Stock
Leonard Steven Chapman, CEO And President at Natera (NASDAQ:NTRA), made a large buy and sell of company shares on October 5, according to a new SEC filing. What Happened: A Form 4... 
Via Benzinga
Topics Regulatory Compliance
Exposures Legal Regulatory
Notable Natera Insider Trades $3M In Company Stock
Burkes Michael Brophy, Chief Financial Officer at Natera (NASDAQ:NTRA), made a large buy and sell of company shares on September 28, according to a new SEC filing. What Happened:... 
Via Benzinga
Topics Regulatory Compliance
Exposures Legal Regulatory
CEO And President Of Natera Trades $3.41 Million In Company Stock
Leonard Steven Chapman, CEO And President at Natera (NASDAQ:NTRA), made a large buy and sell of company shares on September 24, according to a new SEC filing. What Happened: A... 
Via Benzinga
Topics Regulatory Compliance
Exposures Legal Regulatory
Return on Capital Employed Overview: Natera
After pulling data from Benzinga Pro it seems like during Q2, Natera (NASDAQ:NTRA) brought in sales totaling $142.03 million. However, earnings decreased 82.96%, resulting in a... 
Via Benzinga
Natera Q2 Sales Tops Street Estimates On Higher Volumes, Raises FY21 Sales Outlook
Natera Inc's (NASDAQ: NTRA) second-quarter revenues jumped 64% Y/Y $142 million, driven by an increase in test volume and product revenues, sharply ahead of the consensus... 
Via Benzinga
The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 4) Absci, CORP (NASDAQ: ABSI) (... 
Via Benzinga
Analyzing Natera's Unusual Options Activity
On Wednesday, shares of Natera (NASDAQ:NTRA) saw unusual o... 
Via Benzinga
What Does Natera's Debt Look Like?
Over the past three months, shares of Natera (NASDAQ:NTRA) moved higher by 10.31%. Before we understand the importance of debt, let us look at how much debt Natera has.... 
Via Benzinga
Expert Ratings For Natera
Within the last quarter, Natera (NASDAQ:NTRA) has observe... 
Via Benzinga
Analyst Ratings For Natera
Within the last quarter, Natera (NASDAQ:NTRA) has observed... 
Via Benzinga
The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs
Biotech stocks showed a lack of direction in the week ending July 30 amid earnings releases from big pharma companies. Most pharma majors reported strong quarterly results.... 
Via Benzinga
Exposures Product Safety
Expert Ratings for Natera
Analysts have provided the following ratings for Natera (NASDAQ:NTRA) within the last quarter: Last 30 Days 1 Month Ago 2 Months Ago 3 Months Ago Bullish 1 1 0 0... 
Via Benzinga
3 Stocks Insiders Are Buying
When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go... 
Via Benzinga
The Daily Biotech Pulse: J&J, Novartis Report Solid Results, Chembio Soars On COVID Test Order, Lumos Signals Clinical Trial Delay
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 20) Alnylam Pharmaceuticals,... 
Via Benzinga
Natera Sees Deeper Operating Losses In Q2 On Higher Commercialization Costs For New Product Offerings
Natera Inc (NASDAQ: NTRA) expects 2Q'21 revenues of approximately $138 million to $141 million, equivalent to around 60% Y/Y growth. The Company's revenue... 
Via Benzinga
Natera: Q1 Earnings Insights
Shares of Natera (NASDAQ:NTRA) rose in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share fell 64.44% over the past year to ($0.74),... 
Via Benzinga
Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge
Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions. Earnings prints from big name... 
Via Benzinga
Exposures Product Safety
This Explosive Biotech Is Taking On a Huge New Market
Dominant in its core reproductive health market, niche medical diagnostics company Natera now has its sights on the crowded oncology diagnostics space. 
Via The Motley Fool
10 Biggest Price Target Changes For Monday
SVB Leerink raised Natera, Inc. (NASDAQ:NTRA) pr... 
Via Benzinga
Foundation Medicine Launches FoundationOne®Tracker ctDNA Monitoring Assay for Research Use in Partnership with Natera
From Foundation Medicine
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For June 15, 2021
Upgrades According to Raymond James, the prior rating for Welltower Inc (NYSE:WELL) was changed from Market Perform to Strong Buy. For the first quarter, Welltower had an... 
Via Benzinga
Exact Sciences' First-Quarter Results Show Its Strength Under Pressure
Despite ongoing pandemic-related headwinds, the medical diagnostic test maker's revenue grew. So how will it perform as those headwinds dissipate? 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For May 25, 2021
Upgrades For Appian Corp (NASDAQ:APPN), Macquarie upgraded the previous rating of Underperform to Neutral. For the first quarter, Appian had an EPS of $0.06, compared to... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers T2 Biosystems (NASDAQ:TTOO) share... 
Via Benzinga
The Daily Biotech Pulse: Split Verdict For Chemocentryx, NKarta-CRISPR In Cell Therapy Collaboration, Orphazyme's Clinical Trial Setback, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 6) GT Biopharma, Inc. (NASDAQ:... 
Via Benzinga
The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 5) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
Exposures Product Safety
Cramer Gives His Opinion On ContextLogic, Microvision And More
On CNBC's "Mad Money Lightning Round," Jim Cramer said he bets there could be a bit of a run in ContextLogic Inc. (NASDAQ: WISH) because 40% of the float is shorted... 
Via Benzinga
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback